U.S. Meibomian Gland Dysfunction Market Size to Exceed USD 11,199.8 Mn by 2032

The U.S. Meibomian Gland Dysfunction Market, estimated at USD 4,059.8 Mn in 2025, is expected to exhibit a CAGR of 15.6% and reach USD 11,199.8 Mn by 2032.

The market growth is driven by increasing demand for innovative and effective drugs across diverse therapeutic areas. Advances in drug discovery, biopharmaceuticals, and digital technologies are improving treatment outcomes and operational efficiency. Supportive regulations, rising R&D investments, and a strong focus on patient-centric care are creating new opportunities for pharmaceutical companies.

Key players operating in the market are focusing on launching innovative products for the treatment of meibomian gland dysfunction syndrome, which is expected to drive market growth during the forecast period. For instance, in November 2020, TearScience, a part of Johnson and Johnson Vision Care Inc., launched LipiScan and LipiFlow technologies at the American Academy of Ophthalmology’s 2020 meeting. The technologies are used to treat meibomian gland dysfunction (MGD), a cause of dry eye disease. Moreover, In July 2021, Allergan Plc., now a subsidiary of Abbvie Inc., launched REFRESH REPAIR Lubricant Eye Drops, an over-the-counter (OTC) artificial tear formulation. The product is designed to repair and protect the eyes from the harmful effects of dry eye and improve clarity of vision.

U.S. Meibomian Gland Dysfunction Market– Impact of Coronavirus (COVID-19) Pandemic

The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China) in the last months of 2019 as "coronavirus disease 2019" or COVID-19. This virus spread quickly and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.

COVID-19 affected the economy in three main ways: by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to the lockdown, several countries such as India, China, Brazil, and others faced problems with regard to the transportation of equipment from one place to another.

COVID-19 had a positive impact on the U.S. Meibomian Gland Dysfunction market. Key players operating in the market have a robust product pipeline for the treatment of dry eye-associated meibomian gland dysfunction. The players are focusing on changes in clinical enrollment studies associated with COVID-19, which will help to complete the clinical trials on time. For instance, in March 2020, The GtreeBNT team met with the contract research organization (CRO) managing the ARISE-3 trial, to discuss any changes or projected changes in enrollment associated with the COVID-19 virus.  They are also developing contingency plans based on future developments or restrictions enacted by the U.S. and/or World Health Organization. Thus, there have been no major disruptions or delays in ARISE-3 trial and, if modifications are needed in the clinical plan due to COVID-19, GtreeBNT will notify its stockholders immediately through the GtreeBNT website.

U.S. Meibomian Gland Dysfunction Market: Key Developments

In September 2019, OASIS Medical is an eye care solution company, launched Oasis TEARS VISION and Oasis TEARS OMEGA 3, a new line of dietary supplements at Vision Expo West in Las Vegas on September 19, 2019.

In March 2020, RegeneRx, a clinical-stage drug development company announced that GtreeBNT, its Korean partner in the U.S. for the development of RGN-259 for the treatment of dry eye disease, issued an update on the status of the company’s U.S. phase 3 dry eye clinical trial.

In April 2020, the National Centers for Biotechnological Information published results of a study that showed that since January 2020, COVID-19 has become a global pandemic caused by the highly transmissible severe acute respiratory syndrome coronavirus. There have been several reports of eye redness and irritation in COVID-19 patients, both anecdotal and published, suggesting that conjunctivitis may be an ocular manifestation of the SARS-CoV-2 infection.

In November 2021, I-MED Pharma USA  is a division of I-MED Pharma Inc., a privately held Canada based company,  launched I-DROP MGD, a preservative-free, viscoadaptive eye drop containing a lipid designed to enhance and stabilize all three layers of the tear film to treat dry eye.

Browse 34 Market Data Tables and 26 Figures spread through 176 Pages and in-depth TOC on “U.S. Meibomian Gland Dysfunction Market”- Forecast to 2030, U.S. Meibomian Gland Dysfunction Market By Drug Type (Cyclosporine, Omega-3 supplements, Antibacterial Eye Drops, Steroids, AZR MD 001, TP 03, NOV03 (Novatears), and HY02 – Minocycline), By Route of Administration (Oral and Topical), and By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies).

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/us-meibomian-gland-dysfunction-market-4186

Key Takeaways of the U.S. Meibomian Gland Dysfunction Market:

• The U.S. meibomian gland dysfunction market is expected to expand at a CAGR of 15.6%  during the forecast period owing to a robust product pipeline for the treatment of meibomian gland dysfunction. For instance, in December 2021, Aldeyra Therapeutics, Inc., a biotechnology company, announced positive results from its Phase 2b clinical trial of topical ocular reproxalap in patients with dry eye disease associated with meibomian gland dysfunction syndrome. Reproxalap is a first-in-class therapy with a novel mechanism of action, with no significant side effects and rapid onset of action.
• Among drug type, the Cyclosporine segment holds a dominant position in the U.S. meibomian gland dysfunction market in 2022, owing incrasing product approvals for treatment meibomian gland dysfunction. For instance, in August 2018, Sun Pharma received approval for Cequa (cyclosporine ophthalmic solution) 0.09% from the U.S. FDA. The drug is indicated for increasing tear production in patients with dry eye disease. Cequa is the only approved cyclosporine product that incorporates nanomicellar technology and allows better penetration of active molecules into ocular tissues.
• Major players operating in the U.S. Meibomian Gland Dysfunction market include Pfizer, Inc., AbbVie Inc., Johnson and Johnson Vision Care Inc., Bausch Health Companies Inc., Novartis AG, Santen Pharmaceutical Co., Ltd., I-MED Pharma Inc., OASIS Medical, Sentiss Pharma Pvt. Ltd., RegeneRx, Akorn, Inc., AFT Pharmaceuticals, Alcon Inc., Horus Pharma, Mitotech, Novaliq GmbH, Otsuka Pharmaceutical Co. Ltd, Prestige Consumer Healthcare, Santen Pharmaceutical Co. Ltd, Sun Pharmaceutical Industries Ltd, and VISUfarma.